The Grifols crisis has taken Steven F. Mayer by storm. In a statement sent to the National Securities Market Commission (CNMV), the company has announced the resignation of Mayer as executive president and member of the board of directors for “health reasons and other personal reasons by letter addressed to the Board of Directors” . On February 15, the plan for better operations was announced, which has already been launched and which, with its execution, is expected to increase value for shareholders and “improve the debt ratio.”
The Board has appreciated the work carried out by Mayer, who took office last November 2022 at the CNMV. Glanzmann has been a director of Grifols since 2006 and vice-chairman of the company’s board since January 2017, and practically his entire professional career has been linked to the plasma industry.
He has also held positions such as Chairman of Baxter Bioscience, CEO of Immuno International, and Chairman of the European Biotech Group. Glanzmann is currently a director of Alcon Inc., where he chairs the Innovation Committee and is a member of the Compensation and Governance Committees. In addition, he is a founding partner of a San Francisco-based ‘MedTech’ fund.
To date, he has been non-executive vice-chairman of the Grifols Board and chairman of the Sustainability Committee. The company has indicated that “the entire Board will continue with the implementation of the operational improvement plan formulated by Mr. Mayer”, adding that the commitment “is total, a long-term vision for society”.
